Despite improved glycaemic control following the use of injectable therapy, drawbacks of insulin include weight gain, and severe hypoglycaemia and increased risk of death [31, 32], whilst glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been linked to gastrointestinal symptoms such as nausea, vomiting, and diarrhoea [33], which may deter people from using them. The gene discussed is GLP1R; the disease is Hypoglycemia.